NCT00387205 - Study To Assess Long Term Safety Of Pazopanib | Biotech Hunter

Enrollment

188

Participants

Timeline

Start Date

June 20, 2006

Primary Completion Date

February 13, 2013

Study Completion Date

March 8, 2018

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Pazopanib

Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications

Trial Locations (19)

14263

Novartis Investigative Site, Buffalo

27710

Novartis Investigative Site, Durham

29605

Novartis Investigative Site, Greenville

37203

Novartis Investigative Site, Nashville

44106

Novartis Investigative Site, Cleveland

46202

Novartis Investigative Site, Indianapolis

48201

Novartis Investigative Site, Detroit

55404

Novartis Investigative Site, Minneapolis

69373

Novartis Investigative Site, Lyon

80045

Novartis Investigative Site, Aurora

90404

Novartis Investigative Site, Santa Monica

91010

Novartis Investigative Site, Duarte

98405

Novartis Investigative Site, Tacoma

119074

Novartis Investigative Site, Singapore

03756

Novartis Investigative Site, Lebanon

08901

Novartis Investigative Site, New Brunswick

77030-4009

Novartis Investigative Site, Houston

SM2 5PT

Novartis Investigative Site, Sutton

NE7 7DN

Novartis Investigative Site, Newcastle upon Tyne